CN114929738B - 抗nampt抗体及其用途 - Google Patents

抗nampt抗体及其用途

Info

Publication number
CN114929738B
CN114929738B CN202080069890.5A CN202080069890A CN114929738B CN 114929738 B CN114929738 B CN 114929738B CN 202080069890 A CN202080069890 A CN 202080069890A CN 114929738 B CN114929738 B CN 114929738B
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
sequence shown
nampt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080069890.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN114929738A (zh
Inventor
J·G·N·加西亚
D·麦卡恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scuba Therapy Co
Original Assignee
Scuba Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scuba Therapy Co filed Critical Scuba Therapy Co
Publication of CN114929738A publication Critical patent/CN114929738A/zh
Application granted granted Critical
Publication of CN114929738B publication Critical patent/CN114929738B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080069890.5A 2019-08-07 2020-08-07 抗nampt抗体及其用途 Active CN114929738B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962883952P 2019-08-07 2019-08-07
US62/883,952 2019-08-07
PCT/US2020/045511 WO2021026508A1 (en) 2019-08-07 2020-08-07 Anti-nampt antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN114929738A CN114929738A (zh) 2022-08-19
CN114929738B true CN114929738B (zh) 2026-01-02

Family

ID=74503750

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080069890.5A Active CN114929738B (zh) 2019-08-07 2020-08-07 抗nampt抗体及其用途

Country Status (7)

Country Link
US (3) US11142586B2 (https=)
EP (1) EP4010368A4 (https=)
JP (2) JP7802651B2 (https=)
CN (1) CN114929738B (https=)
AU (1) AU2020325315A1 (https=)
CA (1) CA3147020A1 (https=)
WO (1) WO2021026508A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN113614535B (zh) 2018-10-31 2024-08-16 亚利桑那大学评议会 用于辐射诱导的肺损伤的生物标志物和使用方法
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
WO2021195265A1 (en) * 2020-03-24 2021-09-30 Ampio Pharmaceuticals, Inc. Methods for treating diseases associated with respiratory viruses
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN117815243B (zh) * 2023-12-29 2025-01-24 四川大学华西医院 一种化合物在制备治疗肝纤维化的药物以及nampt抑制剂中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170113A1 (en) * 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
CN105055412A (zh) * 2015-08-20 2015-11-18 四川大学 Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480059C (en) 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
WO2004050708A2 (en) 2002-11-29 2004-06-17 Rsr Limited Antibody for the thyrotropin receptor and uses thereof
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US9409983B2 (en) * 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
AU2015357543B2 (en) * 2014-12-05 2021-10-21 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof
PL3560953T3 (pl) * 2014-12-24 2024-05-13 Autolus Limited Komórka
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
US20190023809A1 (en) * 2015-09-03 2019-01-24 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
CN110945128B (zh) * 2017-04-14 2023-11-03 代表亚利桑那大学的亚利桑那董事会 用于治疗肺纤维化的组合物和方法
JP7490565B2 (ja) * 2017-12-29 2024-05-27 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170113A1 (en) * 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
CN105055412A (zh) * 2015-08-20 2015-11-18 四川大学 Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途

Also Published As

Publication number Publication date
EP4010368A1 (en) 2022-06-15
JP2025176044A (ja) 2025-12-03
US11466099B2 (en) 2022-10-11
AU2020325315A1 (en) 2022-03-24
CA3147020A1 (en) 2021-02-11
CN114929738A (zh) 2022-08-19
JP7802651B2 (ja) 2026-01-20
JP2022543658A (ja) 2022-10-13
US11142586B2 (en) 2021-10-12
US20230220113A1 (en) 2023-07-13
US20210070883A1 (en) 2021-03-11
WO2021026508A1 (en) 2021-02-11
US20220056152A1 (en) 2022-02-24
EP4010368A4 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
CN114929738B (zh) 抗nampt抗体及其用途
US11220544B2 (en) Anti-CD166 antibodies and uses thereof
ES2717908T3 (es) Anticuerpos S100A4 y usos terapéuticos de los mismos
JP2019110906A (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
BR112019014694A2 (pt) anticorpos anti-cd47 e usos dos mesmos
BR112019019111A2 (pt) anticorpo de b7-h3, seu fragmento de ligação ao antígeno e seu uso médico
CN101903044A (zh) 对人铁调素具有特异性的抗原结合蛋白
CN117043183A (zh) Tau结合化合物
WO2021110095A1 (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
US9914768B2 (en) Anti-S100A7 antibodies for the treatment and diagnosis of cancer
JP2021500895A (ja) Ａｌｋ７結合タンパク質およびその使用
US20240384005A1 (en) Anti-ngly-1 antibodies and methods of use
HK40080584A (en) Anti-nampt antibodies and uses thereof
US20250011405A1 (en) Treatment and diagnosis of diseases associated to pathogenic fibrosis
JP7564882B2 (ja) Ａｒｅｇに対する抗体及びその用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080584

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant